$188 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 8 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
HRTX | HERON THERAPEUTICS INC | $81,183,000 | -24.0% | 6,197,198 | 0.0% | 43.30% | -2.2% | |
LJPC | LA JOLLA PHARMACEUTICAL CO | $55,941,000 | -26.3% | 3,191,165 | 0.0% | 29.83% | -5.3% | |
RXDX | IGNYTA INC | $21,056,000 | -15.7% | 3,972,800 | 0.0% | 11.23% | +8.3% | |
OPKO HEALTH INCdebt 3.0% 2/1/33 | $19,355,000 | -12.1% | 14,000,000 | 0.0% | 10.32% | +13.0% | ||
BMRN | BIOMARIN PHARMACEUTICAL INC | $7,473,000 | -10.5% | 90,215 | 0.0% | 3.98% | +15.1% | |
CYCC | CYCLACEL PHARMACEUTICALS INC | $1,904,000 | -11.8% | 359,900 | 0.0% | 1.02% | +13.4% | |
LIFE | ATYR PHARMA INC | $601,000 | -32.4% | 279,425 | 0.0% | 0.32% | -13.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
4 | 2024-02-14 |
4 | 2024-02-02 |
4 | 2023-12-18 |
13F-HR | 2023-11-14 |
4 | 2023-10-13 |
13F-HR | 2023-08-14 |
3 | 2023-06-01 |
4 | 2023-06-01 |
4 | 2023-05-30 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.